Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.
Dick P, Grandjean ME, Tissot R · 1983 · Neuropsychobiology 10(4):205-208
What does this source report?
An uncontrolled report described improvement in 48 of 49 evaluable patients; 27% of enrolled patients were lost or unsuitable for evaluation.
- Population and setting
- 67 withdrawal patients enrolled; 49 evaluable
- Evidence type
- Uncontrolled human report
- Preparation
- Ordinary DSIP
- Source language
- eng
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- No control group and substantial exclusion/loss prevent causal conclusions. Not a basis for self-treatment of withdrawal.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Recorded source-check date: 2026-10-01. This date does not imply a completed systematic review.
Open original source or index record ↗
DOI: 10.1159/000118012
Cite and trace this record
Original source: Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors. Neuropsychobiology 10(4):205-208 1983.
Molekul research summary: https://molekul.io/research/dsip-6328354. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry